Wu Xiaohua
Welcome,         Profile    Billing    Logout  
 19 Trials 
33 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
WU, Xiaohua
FLAMES, NCT04169997: A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer

Recruiting
3
393
RoW
IMP4927, Placebos
Impact Therapeutics, Inc.
Ovarian Cancer
02/22
12/22
TQB2450-III-13, NCT06475599: Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer

Not yet recruiting
3
420
RoW
Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Endometrial Cancer
12/27
06/29
MONO-OLA1, NCT04884360 / 2020-005960-68: D9319C00001- 1L OC Mono Global RCT

Jan 2024 - Dec 2024: Acceptance of regulatory submission for 1L BRCAwt ovarian cancer (based on MONO-OLA1 trial)
Jan 2024 - Dec 2024: Data from MONO-OLA1 trial for BRCAwt advanced ovarian cancer
Active, not recruiting
3
366
RoW
Olaparib, Matching placebo
AstraZeneca
Ovarian Cancer
04/25
04/26
NCT06584032: Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

Recruiting
3
412
RoW
fruquintinib, HMPL-013, sintilimab, IBI308, paclitaxel, doxorubicin
Hutchmed
Advanced Endometrial Cancer
01/29
06/29
CHIPRO, NCT04921527: Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer

Recruiting
3
454
RoW
chiauranib, CS2164, Placebo, Paclitaxel, Anzatax
Chipscreen Biosciences, Ltd.
Ovarian Cancer, Relapsed or Refractory, Chiauranib, Paclitaxel
12/24
07/25
COMPASSION-16, NCT04982237: A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Recruiting
3
440
RoW
AK104, paclitaxel, carboplatin, cisplatin, bevacizumab, Placebo
Akeso
Cervical Cancer
04/25
12/25
AK104-305, NCT05235516: A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer

Active, not recruiting
3
636
RoW
AK104, EBRT, BT, cisplatin, Placebo
Akeso
Locally Advanced Cervical Carcinoma
05/26
05/29
TQB2450-II-08, NCT04574284: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

Recruiting
2
196
RoW
TQB2450, Anlotinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Endometrial Cancer
12/21
04/22
SABRINA, NCT04089189: Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer

Recruiting
2
100
RoW
IMP4297
Impact Therapeutics, Inc.
Ovarian Cancer
03/22
08/22
NCT03972722: Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer

Checkmark Presentation of data in patients with PD-L1–positive recurrent or metastatic 2L cervical cancer at SITC 2022
Dec 2022 - Dec 2022: Presentation of data in patients with PD-L1–positive recurrent or metastatic 2L cervical cancer at SITC 2022
Recruiting
2
89
RoW
GLS-010, Full-human anti-pd-1 monoclonal antibodies
Guangzhou Gloria Biosciences Co., Ltd.
Cervical Cancer
05/22
05/23
NCT04836663: A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors

Recruiting
2
90
RoW
TQ-B3525 tablet
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Endometrial Cancer, Cervical Cancer and Ovarian Cancer
09/22
12/22
SHR-1210-II-213, NCT03827837: Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Recruiting
2
265
RoW
SHR-1210, Camrelizumab, Famitinib, Famitinib Malate Capsule
Jiangsu HengRui Medicine Co., Ltd.
Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, Ovarian Cancer Recurrent, Endometrial Cancer
12/22
12/22
NCT05043922: A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma

Recruiting
2
86
Japan, RoW
CYH33
Haihe Biopharma Co., Ltd.
Ovarian Cancer, Recurrent Cancer
06/23
06/23
NCT05112991: Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Recruiting
2
108
RoW
Envafolimab+Lenvatinib, Envafolimab
3D Medicines (Sichuan) Co., Ltd.
Advanced Endometrial Cancer
03/25
10/25
SHR-1316-202, NCT06237257: A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer

Active, not recruiting
2
56
RoW
SHR-1316, Cisplatin Injection/Carboplatin Injection, External Beam Radiotherapy (EBRT)/Brachytherapy, Paclitaxel Injection
Shanghai Shengdi Pharmaceutical Co., Ltd
Locally Advanced Cervical Cancer
12/24
01/25
NCT06241781: Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer

Recruiting
2
64
RoW
GT101 injection, Gemcitabine injection
Grit Biotechnology
Adult
01/27
01/27
WX390-002, NCT06117540: A Study of WX390 in Patients With Advanced Solid Tumors

Recruiting
2
70
RoW
WX390, WXFL10030390
Shanghai Jiatan Pharmatech Co., Ltd
Solid Tumor
06/24
06/24
NCT06434610: A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Recruiting
2
90
RoW
B013, Paclitaxel, Placebo
Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd
Platinum-resistant Recurrent Ovarian Cancer
12/26
12/26
SKB264-II-06, NCT05642780: SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Recruiting
2
240
Europe, Canada, US, RoW
SKB264, Pembrolizumab, Keytruda
Klus Pharma Inc., Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc.
Solid Tumor
11/26
12/27
BGB-290-102, NCT03333915: Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors

Checkmark Approved in China for germline BRCA mutation-associated ovarian, fallopian tube, or primary peritoneal cancer
May 2021 - May 2021: Approved in China for germline BRCA mutation-associated ovarian, fallopian tube, or primary peritoneal cancer
Checkmark Filed for deleterious/suspected deleterious germline BRCA-mut advanced 3L ovarian, fallopian tube/primary peritoneal cancer in China
Jul 2020 - Jul 2020: Filed for deleterious/suspected deleterious germline BRCA-mut advanced 3L ovarian, fallopian tube/primary peritoneal cancer in China
Hourglass Mar 2020 - Jun 2020 : From trial in Chinese patients with 2L ovarian cancer
More
Completed
1/2
128
RoW
Pamiparib, BGB-290
BeiGene
Advanced High-grade Ovarian Cancer, Triple Negative Breast Cancer
08/20
08/21
NCT05357027: HPV16 E6 TCR T Cells for Cervical Carcinoma

Recruiting
1/2
18
RoW
TC-E202 cells, TCR T Cells, IL-2, Fludarabine, Cyclophosphamide Capsules
TCRCure Biopharma Ltd., Fudan University
Cervical Carcinoma
12/24
08/25
NCT06682780: A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

Not yet recruiting
1/2
320
RoW
LM-2417, Docetaxel, Toripalimab/Tirelizumab, Carboplatin, Niraparib, Lenvatinib
LaNova Medicines Limited
Advanced Solid Tumor
12/27
12/29
JSKN003-102, NCT05744427: Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors

Hourglass Dec 2024 - Dec 2024 : Results for HER2-low, U/M BC
Recruiting
1/2
725
RoW
JSKN003
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Solid Tumor
12/24
12/26
PRO1184-001, NCT05579366: Rinatabart Sesutecan (Rina-S) for Advanced Solid Tumors (GCT1184-01/ )

Recruiting
1/2
404
US, RoW
Rina-S, PRO1184, Rinatabart sesutecan, GEN1184, Carboplatin, Bevacizumab, Pembrolizumab
Genmab
Platinum-Resistant Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC), High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer
04/26
10/26
SHR-4375-101, NCT06764628: A Study of SHR-4375 in Subjects With Solid Tumors

Not yet recruiting
1/2
208
RoW
SHR-4375
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Solid Tumors
05/27
05/27
NCT06770881: JSKN033 in Chinese Subjects with Advanced Malignant Tumors

Not yet recruiting
1/2
430
NA
JSKN033
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Malignant Tumors
12/26
12/27
NCT05803018: A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies

Recruiting
1/2
32
RoW
BL-B01D1
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Gynecological Malignant Tumor, Solid Tumor
06/25
06/25
NCT04586335: Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Terminated
1
24
US, RoW
CYH33, Olaparib
Haihe Biopharma Co., Ltd.
Ovarian Cancer, Breast Cancer, Solid Tumor, Prostate Cancer, Endometrial Cancer
02/23
02/23
KUNLUN-001, NCT06375187: Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL) for the Treatment of Advanced Malignant Solid Tumors

Recruiting
1
18
RoW
Engineering Tumor Infiltrating Lymphocytes, GC203 TIL
Shanghai Juncell Therapeutics
Solid Tumor, Gynecologic Cancer, Breast Cancer, Gastrointestinal Cancer, Lung Cancer
11/25
05/27
SPH7485-101, NCT06487455: A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.

Recruiting
1
170
RoW
SPH7485
Shanghai Pharmaceuticals Holding Co., Ltd
Advanced Solid Tumor
12/27
12/27
TIL, NCT05475847: Study of C-052A Cell Therapy in Advanced Cervical Cancer

Recruiting
1
20
RoW
Autologous Tumor Infiltrating Lymphocytes (C-TIL052A) Injection
Fudan University, Cellular Biomedicine Group Ltd.
Cervical Cancer
07/25
07/25
NCT05952947: HRYZ-T101 Injection for HPV18 Positive Solid Tumor

Recruiting
1
32
RoW
HRYZ-T101 Injection, Fludarabine + Cyclophosphamide
HRYZ Biotech Co.
Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Carcinoma of Vagina, Carcinoma of Penis, Anal Cancer, Carcinoma of Vulva
12/27
02/28
NCT06001099: PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale Cancers, PERCEIVE-II

Recruiting
N/A
2935
RoW
Fudan University, Guangzhou Burning Rock Dx Co., Ltd.
Gynecologic Cancer
06/24
12/24
zheng, zhong
No trials found

Download Options